Evidence map›Paper›PMID 36203752›Full record

ArticleFrontiers in medicine2022

Difference in mortality rates in hospitalized COVID-19 patients identified by cytokine profile clustering using a machine learning approach: An outcome prediction alternative.

Ana Cristina Castro-Castro, Lucia Figueroa-Protti, Jose Arturo Molina-Mora, María Paula Rojas-Salas, Danae Villafuerte-Mena, María José Suarez-Sánchez, Alfredo Sanabría-Castro, Carolina Boza-Calvo, Leonardo Calvo-Flores, Mariela Solano-Vargas and 10 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 2 countries.

Ana Cristina Castro-CastroCentro de Investigación en Enfermedades Tropicales (CIET), Universidad de Costa Rica, San José, Costa Rica.
Lucia Figueroa-ProttiCentro de Investigación en Cirugía y Cáncer (CICICA), Universidad de Costa Rica, San José, Costa Rica.
Jose Arturo Molina-MoraCentro de Investigación en Enfermedades Tropicales (CIET), Universidad de Costa Rica, San José, Costa Rica.
María Paula Rojas-SalasCentro de Investigación en Hematología y Trastornos Afines (CIHATA), Universidad de Costa Rica, San José, Costa Rica.
Danae Villafuerte-MenaCentro de Investigación en Hematología y Trastornos Afines (CIHATA), Universidad de Costa Rica, San José, Costa Rica.
María José Suarez-SánchezCentro de Investigación en Hematología y Trastornos Afines (CIHATA), Universidad de Costa Rica, San José, Costa Rica.
Alfredo Sanabría-CastroUnidad de Investigación, Hospital San Juan de Dios CCSS, San José, Costa Rica.
Carolina Boza-CalvoCentro de Investigación en Hematología y Trastornos Afines (CIHATA), Universidad de Costa Rica, San José, Costa Rica.
Leonardo Calvo-FloresCentro de Investigación en Hematología y Trastornos Afines (CIHATA), Universidad de Costa Rica, San José, Costa Rica.
Mariela Solano-VargasCentro de Investigación en Hematología y Trastornos Afines (CIHATA), Universidad de Costa Rica, San José, Costa Rica.
Juan José Madrigal-SánchezCentro de Investigación en Hematología y Trastornos Afines (CIHATA), Universidad de Costa Rica, San José, Costa Rica.
Mario Sibaja-CamposServicio de Neumología, Hospital San Juan de Dios CCSS, San José, Costa Rica.
Juan Ignacio Silesky-JiménezUnidad de Cuidados Intensivos, Hospital San Juan de Dios CCSS, San José, Costa Rica.
José Miguel Chaverri-FernándezDepartamento de Farmacología, Facultad de Farmacia, Toxicología y Farmacodependencia, Universidad de Costa Rica, San José, Costa Rica.
Andrés Soto-RodríguezUnidad de Investigación, Hospital San Juan de Dios CCSS, San José, Costa Rica.
Ann Echeverri-McCandlessUnidad de Investigación, Hospital San Juan de Dios CCSS, San José, Costa Rica.
Sebastián Rojas-ChavesUnidad de Investigación, Hospital San Juan de Dios CCSS, San José, Costa Rica.
Denis Landaverde-RecinosServicio de Oncología Médica, Hospital México CCSS, San José, Costa Rica.
Andreas WeigertFaculty of Medicine, Institute of Biochemistry I, Goethe-University Frankfurt, Frankfurt, Germany.
Javier MoraCentro de Investigación en Enfermedades Tropicales (CIET), Universidad de Costa Rica, San José, Costa Rica.
Universidad de Costa Rica · CRDeutschen Konsortium für Translationale Krebsforschung · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is a disease caused by the novel Coronavirus SARS-CoV-2 causing an acute respiratory disease that can eventually lead to severe acute respiratory syndrome (SARS). An exacerbated inflammatory response is characteristic of SARS-CoV-2 infection, which leads to a cytokine release syndrome also known as cytokine storm associated with the severity of the disease. Considering the importance of this event in the immunopathology of COVID-19, this study analyses cytokine levels of hospitalized patients to identify cytokine profiles associated with severity and mortality. Using a machine learning approach, 3 clusters of COVID-19 hospitalized patients were created based on their cytokine profile. Significant differences in the mortality rate were found among the clusters, associated to different CXCL10/IL-38 ratio. The balance of a CXCL10 induced inflammation with an appropriate immune regulation mediated by the anti-inflammatory cytokine IL-38 appears to generate the adequate immune context to overrule SARS-CoV-2 infection without creating a harmful inflammatory reaction. This study supports the concept that analyzing a single cytokine is insufficient to determine the outcome of a complex disease such as COVID-19, and different strategies incorporating bioinformatic analyses considering a broader immune profile represent a more robust alternative to predict the outcome of hospitalized patients with SARS-CoV-2 infection.

Indexed as

COVID-19CXCL10cytokine profileIL-38SARS-CoV-2

Identifiers

PMID36203752
PMCPMC9530472
OpenAlexW4297906946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.